Foghorn Therapeutics (FHTX) Other financing activities (2019 - 2026)

Foghorn Therapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at $89000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 35.97% year-over-year to $89000.0; the TTM figure through Mar 2026 stood at $433000.0 (down 72.66% YoY), while the FY2025 annual figure was $483000.0, down 81.51% from the prior year.
• Other financing activities for Q1 2026 stood at $89000.0, up from $41000.0 in the prior quarter.
• The five-year high for Other financing activities was $1.4 million in Q3 2024, with the low at $4000.0 in Q4 2024.
• The 5-year median for Other financing activities is $162500.0 (2023), against an average of $420312.5.
• The sharpest annual moves came in 2022 and 2023: Other financing activities slumped 99.96% in 2022, then surged 1062.5% in 2023.
• Foghorn Therapeutics' Other financing activities stood at $16000.0 in 2022, then soared by 1062.5% to $186000.0 in 2023, then sank by 97.85% to $4000.0 in 2024, then soared by 925.0% to $41000.0 in 2025, then soared by 117.07% to $89000.0 in 2026.
• Business Quant data shows FHTX's Other financing activities at $89000.0 in Q1 2026, $41000.0 in Q4 2025, and $49000.0 in Q3 2025.